1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Drugs In Development, 2022, provides an overview of the Bone Metastasis (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. The predisposing factors include certain kinds of cancer (breast, prostate, lung, thyroid, and kidney cancers). Treatment options for bone metastasis are chemotherapy, surgery and radiation therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Bone Metastasis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Bone Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Bone Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 3, 10, 1, 13 and 2 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 9, 1 and 1 molecules, respectively.
Bone Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Metastasis (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bone Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bone Metastasis (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bone Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bone Metastasis (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bone Metastasis (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bone Metastasis (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Bone Metastasis - Overview
- Bone Metastasis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Bone Metastasis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Bone Metastasis - Companies Involved in Therapeutics Development
- Bone Metastasis - Drug Profiles
- Bone Metastasis - Dormant Projects
- Bone Metastasis - Discontinued Products
- Bone Metastasis - Product Development Milestones
- Featured News & Press Releases
- Aug 31, 2021: Qilu Pharmaceutical Co Ltd received the notice of acceptance
- Dec 15, 2020: Luye Pharma Group : Voluntary announcement denosumab injection (LY01011) commenced phase III clincal trial in China
- Oct 28, 2020: CSPC Pharmaceutical Group : Voluntary announcement first patient dosed in the phase 1 clinical trial of investigational new drug “ALMB-0168”
- Sep 15, 2020: CSPC Pharmaceutical Group: Voluntary Announcement Investigational New Drug “ALMB-0168” obtains clinical trial approval in China
- Nov 27, 2019: CSPC Pharmaceutical: Submission Of clinical trial application for investigational first-in-class new drug ALMB-0168 in Australia
- Jan 05, 2018: NeuClone Discloses Details of its Fifth Product: A Biosimilar Candidate for Prolia/XGEVA (Denosumab)
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Bone Metastasis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Bone Metastasis - Dormant Projects, 2022
- Bone Metastasis - Dormant Projects, 2022 (Contd..1)
- Bone Metastasis - Dormant Projects, 2022 (Contd..2)
- Bone Metastasis - Discontinued Products, 2022
- Number of Products under Development for Bone Metastasis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ablynx NV
- Airsea (Taizhou) Pharmaceutical Ltd
- AlaMab Therapeutics Inc
- Aptacure Therapeutics Ltd
- Better Life Pharmaceuticals Inc
- Biocon Ltd
- BiologicsMD Inc
- BioNTech SE
- Crescendo Biologics Ltd
- CSPC Pharmaceutical Group Ltd
- Eden Biologics Inc
- Genor BioPharma Co Ltd
- Hetero Labs Ltd
- Hualan Biological Engineering Inc
- ITM Isotope Technologies Munich SE
- Jiangsu Rhentai Pharmaceutical Biotechnology Co Ltd
- Jiangsu T-mab BioPharma Co Ltd
- Livzon Pharmaceutical Group Co Ltd
- Lupin Ltd
- Luye Pharma Group Ltd
- Mabwell Shanghai Bioscience Co Ltd
- MetCure Therapeutics LLC
- NeuClone Pty Ltd
- Orion Biotechnology Canada Ltd
- PEKKIP Oncology Alliance AG
- Qilu Pharmaceutical Co Ltd
- QSAM Therapeutics Inc
- Sandoz International GmbH
- Serene LLC
- Shanghai Henlius Biotech Inc
- Sonnet BioTherapeutics Holdings Inc
